Visual Universitätsmedizin Mainz

Univ.-Prof. Dr. rer. nat. Tobias Bopp

Univ.-Prof. Dr. rer. nat. Tobias Bopp

General Information

E-mail

 boppt@uni-mainz.de

Current position

W2 Professor

 

Academic Education

1997 - 2003
  • Biology (Diploma), Johannes Gutenberg University Mainz, Germany, E. Schmitt

 

Scientific Degrees

PhD thesis
  • Dr. rer. nat. ("magna cum laude"), Institute for Immunology, Johannes Gutenberg University Mainz, 2006, E. Schmitt

 

Professional Career

2012 - present
  • W2 Professor for Molecular Immunology, Institute for Immunology, Johannes Gutenberg University Mainz
2008 - 2011
  • Groupleader, Institute for Immunology, Johannes Gutenberg University Mainz, Prof. H. Schild
2006 - 2008
  • Postdoctoral Fellow, Institute for Immunology, Johannes Gutenberg University Mainz, Prof. E. Schmitt

 

Honours and Other Activities

2017
  • Speaker and coordinator of the "Forschungszentrum für Immuntherapie" (FZI) at the University Medical Center of the Johannes Gutenberg University Mainz
2016
  • Member of the Steering Committee of the "Forschungszentrum für Immuntherapie" (FZI) at the University Medical Center of the Johannes Gutenberg University Mainz
  • Member of the NOVARTIS Advisory Board for Immunology
  • Faculty member of the German Immuneregulation Meeting
  • Member of the advisory board of the Comprehensive Cancer Center Mainz
2014
  • Member of the Teaching committee of the "Forschungszentrum für Immuntherapie" (FZI) at the University Medical Center of the Johannes Gutenberg University Mainz
2013
  • Elected Spokesman of the Section "T cells: Subpopulations and Functions" within the German Society for Immunology (DGfI)
  • Speaker of the Members of the "Mainz Research School of Translational Biomedicine" (TRANSMED)
2012
  • Member of the PhD Thesis Evaluation committee at the University of Oslo, Norway
  • Auswahlsymposium zum "Paul Ehrlich- und Ludwig Darmstaedter-Nachwuchspreis"
2010
  • "Fritz und Ursula Melchers Award" of the DGfI
  • Administration of animal experiments (according to FELASA C)
2008 - present
  • Referee for international scientific journals (Cell, Nature Reviews Immunology, Nature Immunology, Immunity, EMBO, JEM, JCI, JACI, TII, Blood, etc.)
2008
  • Founding member of the "Forschungszentrum für Immuntherapie" (FZI) at the University Medical Center of the Johannes Gutenberg University Mainz
  • Boehringer Ingelheim Award
2007 - 2009
  • Promotion by the Carl-Zeiss-Foundation

 

Selected Publications

  1. Ulges A*, Witsch EJ*, Pramanik G, Klein M, Birkner K, Bühler U, Wasser B, LuessiF, Stergiou N, Dietzen S, Brühl TJ, Bohn T, Bündgen G, Kunz H, Waisman A, Schild H, Schmitt E, Zipp F$, Bopp T$ (2016). Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development. Proc Natl Acad Sci U S A. 113: 10145-50.
  2.  

  3. Ulges A, Klein M, Reuter S, Gerlitzki B, Hoffmann M, Grebe N, Staudt V, Stergiou N, Bohn T, Brühl T-J, Muth S, Yurugi H, Rajalingam K, Bellinghausen I, Tuettenberg A, Hahn S, Reißig S, Haben I, Zipp F, Waisman A, Probst HC, Beilhack A, Buchou T, Filhol-Cochet O, Boldyreff B,  Breloer M, Jonuleit H, Schild H, Schmitt E, Bopp T (2015) Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. Nat. Immunol. 16: 267–275
  4.  

  5. Niedbala W, Besnard A-G, Nascimento DC, Donate PB, Sonego F, Yip E, Guabiraba R, Chang H-D, Fukada SY, Salmond RJ, Schmitt E, Bopp T, Ryffel B & Liew FY (2014) Nitric oxide enhances Th9 cell differentiation and airway inflammation. Nat Commun 5: 4575
  6.  

  7. Schmitt E, Klein M & Bopp T (2013) Th9 cells, new players in adaptive immunity. Trends Immunol. 48: 115–125
  8.  

  9. Vaeth M*, Gogishvili T*, Bopp T*, Klein M, Berberich-Siebelt F, Gattenloehner S, Avots A, Sparwasser T, Grebe N, Schmitt E, Hünig T, Serfling E & Bodor J (2011) Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cell c1 (NFATc1). Proceedings of the National Academy of Sciences of the United States of America 108: 2480–2485.
  10.  

  11. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N, Gerlitzki B, Hoffmann M, Ulges A, Taube C, Dehzad N, Becker M, Stassen M, Steinborn A, Lohoff M, Schild H, Schmitt E & Bopp T (2010) Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33: 192–202
  12.  

  13. Bopp T, Dehzad N, Reuter S, Klein M, Ullrich N, Stassen M, Schild H, Buhl R, Schmitt E & Taube C (2009) Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J. Immunol. 182: 4017–4024
  14.  

  15. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang H-D, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A & Huehn J (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5: e38
  16.  

  17. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S, Stoll S, Schild H, Staege MS, Stassen M, Jonuleit H & Schmitt E (2007) Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204: 1303–1310
  18.  

  19. Bopp T, Palmetshofer A, Serfling E, Heib V, Schmitt S, Richter C, Klein M, Schild H, Schmitt E & Stassen M (2005) NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells. J. Exp. Med. 201: 181–187

* joint first authors, $ joint senior authors

Institut für Immunologie

Universitätsmedizin Mainz
Geb. 308A, 2./3.OG
Langenbeckstr. 1
55131 Mainz
Tel: +49 (0)6131-17 6198
Fax: +49 (0)6131-17 6202